These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38175439)

  • 1. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
    Bruehl FK; Osman MM; Chen D; Dalland JC
    J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Consensus Classification of myelodysplastic syndromes and related entities.
    Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
    Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the International Consensus Classification of myelodysplastic syndromes.
    Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
    Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
    Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms.
    Chopra S; Bailey NG
    Am J Clin Pathol; 2023 Dec; 160(6):566-570. PubMed ID: 37587830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.
    Zhang Y; Wu J; Qin T; Xu Z; Qu S; Pan L; Li B; Wang H; Zhang P; Yan X; Gong J; Gao Q; Gale RP; Xiao Z
    Leukemia; 2022 Dec; 36(12):2875-2882. PubMed ID: 36224330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the 5
    Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
    Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
    Huber S; Baer C; Hutter S; Dicker F; Meggendorfer M; Pohlkamp C; Kern W; Haferlach T; Haferlach C; Hoermann G
    Leukemia; 2023 Jul; 37(7):1413-1420. PubMed ID: 37120689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and comparison of 5th edition World Health Organization classification (WHO 2022) and International Consensus Classification proposals for MDS-SFB31.
    Liu L; Li B; Xu Z; Qin T; Jia Y; Qu S; Zhang Y; Wu J; Cai W; Pan L; Gao Q; Jiao M; Xiao Z
    Br J Haematol; 2024 Sep; 205(3):942-946. PubMed ID: 38654443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
    Baumgartner F; Baer C; Bamopoulos S; Ayoub E; Truger M; Meggendorfer M; Lenk M; Hoermann G; Hutter S; Müller H; Walter W; Müller ML; Nadarajah N; Blombery P; Keller U; Kern W; Haferlach C; Haferlach T
    Blood; 2024 Mar; 143(12):1139-1156. PubMed ID: 38064663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
    Falini B; Martelli MP
    Am J Hematol; 2023 Mar; 98(3):481-492. PubMed ID: 36606297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
    Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
    Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on
    Yun J; Kim HR
    Ann Lab Med; 2025 Jan; 45(1):36-43. PubMed ID: 39044692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
    Fontana D; Elli EM; Pagni F; Piazza R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
    Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of WHO-5 and ICC classifications in a series of myeloid neoplasms, considerations for hematopathologists and molecular pathologists.
    Moore ME; Williams E; Pelkey L; Courville EL
    Cancer Genet; 2024 Aug; 286-287():25-28. PubMed ID: 38964162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.